Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab-Reference-Cited by-同舟云学术

Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab

Published:2019-04-01 Issue:7 Volume:3 Page:980-983
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Lai Catherine,Ranpura Vishal,Wu Colin,Olnes Matthew J.,Parikh Ankur R.,Shenoy Aarthi,Thompson Julie,Weinstein Barbara,Scheinberg Phillip,Barrett A. John,Desmond Ronan,Young Neal S.,Hourigan Christopher S.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/3/7/980/1743680/advances030411.pdf

Reference15 articles.

1. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Fenaux,2014

2. Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients;Okamoto;Int J Hematol,1997

3. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy;Sloand;J Clin Oncol,2008

4. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions;Sloand;J Clin Oncol,2010

5. Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm;Füreder;Wien Klin Wochenschr,2017

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification;Frontiers in Immunology;2022-09-23

2. From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review;Diagnostics;2021-10-26

3. Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia;Cancers;2021-10-08

4. Immune Therapies for Hematologic Malignancies;Cancers;2021-01-15

5. Immunotherapies for Myelodysplastic Syndromes: Current State and Future Developments;Erciyes Medical Journal;2021